Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Net Income towards Common Stockholders (2018 - 2025)

Eton Pharmaceuticals' Net Income towards Common Stockholders history spans 7 years, with the latest figure at $1.5 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 347.99% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.6 million, a 20.35% decrease, with the full-year FY2025 number at -$4.6 million, down 20.35% from a year prior.
  • Net Income towards Common Stockholders hit $1.5 million in Q4 2025 for Eton Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for ETON hit a ceiling of $5.1 million in Q1 2021 and a floor of -$6.1 million in Q3 2021.
  • Historically, Net Income towards Common Stockholders has averaged -$1.0 million across 5 years, with a median of -$1.6 million in 2022.
  • Biggest five-year swings in Net Income towards Common Stockholders: soared 392.62% in 2023 and later tumbled 407.34% in 2025.
  • Tracing ETON's Net Income towards Common Stockholders over 5 years: stood at $1.0 million in 2021, then fell by 12.22% to $912000.0 in 2022, then tumbled by 347.37% to -$2.3 million in 2023, then skyrocketed by 73.49% to -$598000.0 in 2024, then surged by 347.99% to $1.5 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for ETON at $1.5 million in Q4 2025, -$1.9 million in Q3 2025, and -$2.6 million in Q2 2025.